- Home
- BCYC
as 02-21-2025 4:00pm EST
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
Upcoming Earnings Alert:
Get ready for potential market movements as Bicycle Therapeutics plc BCYC prepares to release earnings report on 25 Feb 2025.
| Founded: | 2009 | Country: | United Kingdom |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 896.2M | IPO Year: | 2019 |
| Target Price: | $33.25 | AVG Volume (30 days): | 275.5K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.14 - $28.67 | Next Earning Date: | 02-25-2025 |
| Revenue: | $36,898,000 | Revenue Growth: | 48.60% |
| Revenue Growth (this year): | 41.07% | Revenue Growth (next year): | -18.03% |
Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Jan 2 '25 | Sell | $14.42 | 4,223 | $60,119.83 | 123,722 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Jan 2 '25 | Sell | $14.42 | 2,118 | $30,000.36 | 55,280 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Jan 2 '25 | Sell | $14.61 | 4,595 | $67,292.75 | 34,832 | |
| Crockett Nigel | BCYC | CHIEF BUSINESS OFFICER | Jan 2 '25 | Sell | $14.42 | 3,519 | $50,200.47 | 51,053 | |
| Young Alethia | BCYC | Chief Financial Officer | Jan 2 '25 | Sell | $14.09 | 1,395 | $19,655.55 | 45,605 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Jan 2 '25 | Sell | $14.42 | 5,514 | $78,310.02 | 99,788 | |
| Arroyo Santiago | BCYC | CHIEF DEVELOPMENT OFFICER | Jan 2 '25 | Sell | $14.09 | 4,943 | $69,646.87 | 69,057 | |
| Lee Kevin | BCYC | CHIEF EXECUTIVE OFFICER | Jan 2 '25 | Sell | $14.42 | 12,130 | $172,952.42 | 495,026 | |
| BAKER BROS. ADVISORS LP | BCYC | Director10% Owner | Dec 13 '24 | Buy | $14.00 | 1,485,397 | $21,230,384.81 | 8,666,247 |
Latest Bicycle Therapeutics plc News
BCYC Breaking Stock News: Dive into BCYC Ticker-Specific Updates for Smart Investing
Insider Monkey
8 days ago
Bicycle Therapeutics (BCYC): Among The Small–Cap Stocks Insiders Are Selling Recently
Simply Wall St.
17 days ago
Bicycle Therapeutics (NASDAQ:BCYC) shareholders have endured a 74% loss from investing in the stock three years ago
Business Wire
17 days ago
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Business Wire
19 days ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
Business Wire
a month ago
Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business Wire
2 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barrons.com
2 months ago
First Solar, Frontier Communications, and More Stocks See Action From Activist Investors
Compare BCYC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCYC Bicycle Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.